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Patients with type 1 diabetes exhibit altered 
cerebral metabolism during hypoglycemia
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Patients with type 1 diabetes mellitus (T1DM) experience, on average, 2 to 3 hypoglycemic episodes per week. 
This study investigated the effect of hypoglycemia on cerebral glucose metabolism in patients with uncom-
plicated T1DM. For this purpose, hyperinsulinemic euglycemic and hypoglycemic glucose clamps were per-
formed on separate days, using [1-13C]glucose infusion to increase plasma 13C enrichment. In vivo brain 13C 
magnetic resonance spectroscopy was used to measure the time course of 13C label incorporation into different 
metabolites and to calculate the tricarboxylic acid cycle flux (VTCA) by a one-compartment metabolic model. 
We found that cerebral glucose metabolism, as reflected by the VTCA, was not significantly different comparing 
euglycemic and hypoglycemic conditions in patients with T1DM. However, the VTCA was inversely related to 
the HbA1C and was, under hypoglycemic conditions, approximately 45% higher than that in a previously inves-
tigated group of healthy subjects. These data suggest that the brains of patients with T1DM are better able to 
endure moderate hypoglycemia than those of subjects without diabetes.
Introduction
Patients with type 1 diabetes mellitus (T1DM) experience on 
average 2 hypoglycemic episodes per week and 1 severe episode 
of hypoglycemia each year (1). Because the brain depends almost 
exclusively on glucose, recurrent hypoglycemia may be a threat for 
cognitive dysfunction and cerebral damage. Patients with T1DM 
are at increased risk for accelerated cognitive decline and possibly 
for dementia (2, 3). Interestingly, however, patients with T1DM 
enduring recurrent episodes of severe hypoglycemia do not appear 
at greater risk of developing cognitive function impairment than 
patients without such a history (4). This suggests that recurrent 
hypoglycemia can induce protective adaptations with respect to 
cerebral glucose metabolism or that hyperglycemia is at least as 
detrimental for the brain as hypoglycemia.
Recently, we showed that brain glucose metabolism in healthy 
subjects at glucose levels of approximately 3 mmol/l did not differ 
from that at normal glucose levels, as reflected by similar tricarboxy-
lic acid (TCA) cycle rates (VTCA) (5). This remarkable maintenance 
of normal VTCA during symptomatic hypoglycemia indicates that 
the glucose threshold for effects on cerebral metabolism lies below 
3 mmol/l, either because the brain can endure low glucose levels or 
because entrance of nonglucose energy substrates such as lactate 
compensates for the fall in glucose (6–9). Whether these findings can 
be extrapolated to patients with T1DM remains to be determined.
This study was therefore undertaken to investigate the effect of 
hypoglycemia on brain glucose metabolism in a representative group 
of patients with longstanding, uncomplicated, reasonably well-con-
trolled T1DM. To do so, we used 13C magnetic resonance spectros-
copy (MRS) of the human brain during euglycemic and hypogly-
cemic glucose clamps with infusion of [1-13C]glucose, as described 
previously (5, 10). With this approach, it is possible to directly assess 
the effects of hypoglycemia on cerebral glucose metabolism and 
therefore to compare VTCA under euglycemic and hypoglycemic con-
ditions. In addition, we were able to compare the results acquired in 
the patient group to data previously obtained in subjects without 
diabetes, who had undergone a similar protocol (5).
Results
To assess the metabolic effects of hypoglycemia in patients with 
T1DM, a total of 8 hyperinsulinemic euglycemic and 8 hypoglyce-
mic clamps were performed. Six patients completed both clamps 
(on separate days), 2 patients completed only the euglycemic clamp, 
and 2 other patients completed only the hypoglycemic clamp.
The clamps started with infusion of a 30 ml 100% [1-13C]glucose 
bolus to rapidly increase plasma 13C enrichment for steady-state 
conditions. As a consequence, plasma glucose and glucose 13C 
enrichment initially peaked (Figure 1). Thereafter, plasma glu-
cose was maintained at 5.0 ± 0.2 mmol/l or 2.9 ± 0.2 mmol/l, as 
intended. Plasma glucose 13C enrichment stabilized at around 30% 
during both euglycemic and hypoglycemic clamps.
Hypoglycemia stimulated the release of the glucose counterregu-
latory hormones, adrenalin, noradrenalin, cortisol, and growth 
hormone (Figure 2), but not that of glucagon, as is characteris-
tic for patients with longstanding T1DM. Although not formally 
addressed by questionnaires, all patients correctly identified the 
hypoglycemic clamp, indicating normal hypoglycemic awareness.
13C MRS was performed to assess the tissue concentrations of 
13C-labeled cerebral metabolites derived from glucose during the 
hyperinsulinemic clamps. Metabolic fluxes were calculated by 
fitting time courses of these metabolite concentrations with the 
one-compartment model, as presented elsewhere (5). This model 
was used to enable quantification and comparison of cerebral glu-
cose metabolism under the two glycemic conditions. Input fac-
tors for the model included (a) plasma concentrations and plasma 
13C isotopic enrichment of glucose and lactate and (b) the time 
courses of 13C incorporation into glutamate C4 (Glu4) and glu-
tamate C3 (Glu3), derived from the 13C magnetic resonance (MR) 
spectra of the brain (Figure 3) that were measured sequentially, 
with a time resolution of 2.5 minutes.
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Plasma lactate concentrations and lactate 13C enrichment 
increased over the first 20 minutes of the clamp. Thereafter, 
plasma lactate levels stabilized at around 1.42 ± 0.03 mmol/l. 
Plasma lactate 13C isotopic enrichment continued to increase 
during the euglycemic clamp and tended to stabilize during 
hypoglycemia (Figure 4).
The time courses of isotope incorporation into glucose metab-
olites in the brain tissue showed greater increase of 13C Glu4 
than of Glu3, consistent with Glu4 being labeled during the first 
turn of the TCA cycle and Glu3 being labeled during the second, 
irrespective of the glycemic condition. The concentrations of 
both Glu4 and Glu3 were lower during the hypoglycemic clamp 
than during the euglycemic clamp (Figure 5), as was expected 
from the slightly lower plasma glucose 13C enrichment values 
during hypoglycemia.
The free flux parameters, VTCA, Vdil (representing the dilution of 
lactate), and Vgln (representing the efflux of glutamine), of the met-
abolic model were adjusted to best fit the time courses of Glu4 and 
Glu3 levels. Note that the model was applied to fit all individual 
data sets but that, for reasons of clarity, Figure 5, C and D, shows 
the averaged fits of the time courses of Glu4 and Glu3 on top of 
the averaged data.
In patients with T1DM, calculated values for VTCA were not dif-
ferent under euglycemic or hypoglycemic conditions (0.59 ± 0.19 
μmol/g/min versus 0.62 ± 0.15 μmol/g/min, euglycemia versus 
hypoglycemia, respectively; P = 0.72; Figure 6). This did not materi-
ally change when only patients for whom there were complete 
data sets under both glycemic conditions were included (n = 6; 
0.57 ± 0.21 μmol/g/min versus 0.58 ± 0.11 μmol/g/min, euglycemia 
versus hypoglycemia, respectively; P = 0.90). To explore the role of 
Figure 1
Plasma glucose concentration and 13C enrichment during clamp studies. (A) Plasma glucose levels and (B) glucose 13C enrichment during 
euglycemic and hypoglycemic clamps. All data are expressed as mean ± SEM.
Figure 2
Counterregulatory hormone levels. Levels of plasma glucagon, adrenalin, noradrenalin, growth hormone, and cortisol at baseline (BL) and at the 
end (End) of the euglycemic and hypoglycemic clamp. All data are expressed as mean ± SEM. *P < 0.05 compared with corresponding baseline 
value. †P < 0.05 compared with end value of euglycemic clamp.
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glycemic control as a surrogate measure of hypoglycemic burden, 
we investigated the relationship between the levels of VTCA and gly-
cosylated hemoglobin (HbA1C) and found that lower HbA1C levels 
were associated with higher VTCA levels (r = 0.56, P < 0.01) (Figure 7).
Compared with results obtained in healthy volunteers (pub-
lished previously, ref. 5), the VTCA in patients with T1DM was 
significantly higher under hypoglycemic conditions (0.43 ± 0.08 
μmol/g/min versus 0.62 ± 0.15 μmol/g/min; P = 0.014; Figure 6). 
There were no significant differences in Vdil or Vgln between healthy 
subjects and patients with T1DM or between glycemic states (Sup-
plemental Figure 1; supplemental material available online with 
this article; doi:10.1172/JCI62742DS1).
Discussion
In this study, we examined the effect of hypoglycemia on brain 
glucose metabolism in patients with uncomplicated T1DM. The 
major observation of this study is that brain glucose metabolism, 
as reflected by the VTCA, was about similar under euglycemic and 
hypoglycemic conditions, analogous to previous results obtained 
in healthy subjects (5). However, when comparing patients with 
T1DM with controls, we found that the VTCA was approximately 
45% higher in patients than in controls under hypoglycemic condi-
tions. We also found that VTCA was inversely correlated with HbA1C 
in patients with T1DM. These findings suggest adaptations to 
endure hypoglycemia in the type 1 diabetic brain that are not pres-
ent in the nondiabetic brain. Since deeper hypoglycemia will even-
tually cause brain glucose metabolism to deteriorate, these adapta-
tions may shift such deterioration to occur at lower plasma glucose 
values in patients with T1DM than in subjects without diabetes.
A few studies have directly compared cerebral glucose metabo-
lism in patients with T1DM with that in nondiabetic controls, yet 
in none of these studies was cerebral glucose metabolism directly 
assessed under hypoglycemic conditions. Henry et al. reported no 
differences in VTCA between patients with T1DM and hypoglyce-
mia unawareness and healthy controls, as measured by 13C MRS. 
However, their study was conducted under hyperglycemic rather 
than under hypoglycemic conditions (11), clearly indicating that 
findings obtained during hyperglycemia cannot be extrapolated to 
include hypoglycemia. A PET study found no differences in brain 
glucose metabolism during hypoglycemia between patients with 
T1DM and controls (12), which is contrary to our findings. How-
ever, the measurement of glucose metabolism in this PET study 
was based on the rate of blood-to-brain glucose uptake, rather 
than on the quantification of glucose metabolites. The much 
milder level of hypoglycemia attained during the clamp (plasma 
glucose, 3.6 mmol/l) and the poor level of glycemic control of the 
patients enrolled (HbA1C 10.1%) could explain their findings and 
make a direct comparison with our study difficult.
Figure 3
13C MR spectrum. Representative MR spectrum acquired in 15 minutes after correction for baseline spectra to remove residual fat contamination 
(note that myo-inositol signal is also not visible because the concentration in the reference spectra is the same as in the dynamic spectra); this is 
an example of a spectrum fitted in jMRUI to derive concentrations of different labeled metabolites. ppm, parts per million.
Figure 4
Plasma lactate 13C enrichment during clamps. Plasma lactate 13C enrichment during (A) euglycemic and (B) hypoglycemic clamps. Patients 
with T1DM are represented by black symbols; shaded areas represent values in healthy subjects, as reported in ref. 5. All data are 
expressed as mean ± SEM.
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Most patients with T1DM experience hypoglycemic events on 
a regular basis. Many patients and care providers are concerned 
that structural abnormalities in white and gray matter and the 
increased risk of dementia and cognitive dysfunction in T1DM 
may (in part) be due to recurrent (severe) hypoglycemia (1, 13–15). 
Although severe hypoglycemia may adversely affect brain anat-
omy and brain function, particularly in the very young (16) and 
potentially in the elderly, our findings provide some reassurance 
for patients that moderate hypoglycemia, such as tested here, 
has limited effects on cerebral energy metabolism. Whether such 
results extend to other aspects of brain structure or function can-
not be derived from our data.
Since hypoglycemia threatens brain function, it seems plausi-
ble that recurrent hypoglycemia initiates an adaptive response 
to protect the brain against future insults. The inverse correla-
tion between HbA1C and VTCA indeed suggests a role of prior 
hypoglycemic exposure to the higher VTCA in patients with 
T1DM with a similarly protective effect, although we cannot 
with certainty rule out an effect of diabetes per se. A variety of 
adaptive mechanisms have previously been suggested, includ-
ing enhanced brain glucose uptake (17, 18), increased storage of 
glycogen in the brain (19, 20), or use of nonglucose compounds 
(6–9, 21, 22). However, most of these suggestions lack sufficient 
support from studies in humans. For instance, in contrast to 
rodent data (23, 24), studies in humans have generally failed to 
confirm that recurrent or prolonged hypoglycemia increases 
brain glucose uptake during subsequent hypoglycemia (25–27). 
Also, the potential contribution of glycogen supercompensation 
as a clinically meaningful adaptation to recurrent hypoglycemia 
in T1DM has recently been questioned (28).
Figure 5
Brain glutamate 13C enrichment over time. Brain Glu4 and Glu3 concentrations during (A) euglycemic and (B) hypoglycemic clamps, (C and 
D) together with the respective fits (solid lines) by the metabolic model. Patients with T1DM are represented by black symbols; shaded areas 
represent values in healthy subjects, as reported in ref. 5. All data were individually quantified and fitted and averaged afterward. All data are 
expressed as mean ± SEM.
Figure 6
VTCA. VTCA during euglycemic and hypoglycemic clamps in patients with 
T1DM (this study) and healthy subjects (5). Individual symbols rep-
resent individual patients or healthy subjects; horizontal bars indicate 
the mean. *P = 0.014.
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Lactate can serve as an alternative fuel for the brain under condi-
tions of glucopenia. Its metabolism shares pathways downstream 
from pyruvate into the TCA cycle with those of glucose. Net uptake 
of lactate by the brain may explain why 13C enrichment of plasma 
lactate continued to increase during euglycemia but not during 
hypoglycemia. Increased capacity to take up monocarboxylic acids, 
such as lactate, from the plasma into the brain during hypoglyce-
mia has been observed in patients with T1DM with hypoglycemia 
unawareness, presumably as adaptation to recurrent hypoglyce-
mia (29). Thus, enhanced lactate uptake may have contributed to 
the observed faster VTCA for patients with T1DM in our study, as 
we previously showed that brain glucose content and transport 
into the brain did not differ between patients and controls during 
hypoglycemia (30). Interestingly, VTCA was also increased in animals 
exposed to recurrent hypoglycemia, but only under euglycemic con-
ditions, while it was reduced under hypoglycemic conditions and 
the consumption of nonglucose compounds appeared unaltered 
under either condition (31). The authors suggested that increased 
GABA levels during hypoglycemia might have inhibited neuronal 
metabolism (31). The discrepancy with our data may be due to dif-
ferences in species but also to a different study design, since our 
patients were instructed to avoid hypoglycemia for at least 24 hours 
prior to the clamps and were exposed to less severe hypoglycemic 
conditions. Since patients with T1DM and hypoglycemia unaware-
ness do not appear to have a greater VTCA under hyperglycemic con-
ditions (11), it seems that the metabolic response we observed is 
specific for the particular experimental conditions.
A potential benefit of increased brain metabolism under hypogly-
cemia may be increased ability to endure hypoglycemia. Studies in 
rats have indicated that exposure to recurrent (moderate) hypoglyce-
mia protects against the development of brain damage or cognitive 
decline from subsequent severe hypoglycemia (32). Indirect evidence 
for this notion is provided by a nested case-control study showing 
that patients with T1DM with at least one severe episode of hypo-
glycemia during follow-up tended to be at lower risk of cardiovas-
cular events, including strokes, than patients without such events 
(33). A recent report found that hypoglycemia caused less regional 
brain deactivation during working memory tasks in patients with 
T1DM and recurrent hypoglycemia than in healthy subjects (34). 
The authors interpreted this as a form of cerebral inefficiency, in 
that the patients needed to engage more brain regions to preserve 
cognitive function during hypoglycemia. However, it could also be 
interpreted as greater ability to resist hypoglycemia, which would 
be consistent with the findings of this study. Indeed, there was an 
inverse correlation between HbA1C and brain activation, very similar 
to the relationship we observed between HbA1C and VTCA.
The strength of our study is that we were able to measure brain 
glucose metabolism with 13C MRS under hypoglycemic conditions 
in vivo in a relevant population at high risk of recurrent hypogly-
cemia. There are also limitations; our measurements were done 
in a voxel in the occipital cortex, a general limitation of brain 13C 
MRS, so that we cannot vouch for other brain regions. Also, the 
metabolic modeling requires a number of assumptions on cere-
bral metabolite concentrations and fluxes. These assumptions 
were identical to those used before (5), and therefore the same 
limitations apply. It was not possible to assess cognitive func-
tion during the experiments, as movement artifacts would have 
disturbed the highly vulnerable MR measurements. Besides, it 
should be acknowledged that very complex tasks would have been 
required to detect cognitive changes during moderate hypoglyce-
mia. No attempt was made to assess overall cognitive function in 
the patients or in the control subjects investigated earlier.
In conclusion, hypoglycemia does not affect brain glucose 
metabolism in patients with longstanding, uncomplicated T1DM, 
indicating that alternative sources of energy, such as lactate, can be 
used by the brain when glucose delivery falls. We also found that 
the VTCA during hypoglycemia was higher in patients with T1DM 
than in healthy controls, which we postulate to be the result of 
cerebral adaptations to chronic recurrent hypoglycemic episodes.
Methods
Subjects
Ten patients with T1DM were included in this study (see Table 1 for patient 
characteristics). All were free from microvascular complications, except for 
background retinopathy, and they used no medications other than insulin, 
thyroxin supplementation (provided that both the dose and serum thyroxin 
levels were stable), or oral contraceptives. All subjects had at least finished 
secondary school, and all but one were in professional jobs. Hypoglycemia 
unawareness was excluded by a Dutch translation of the Cox questionnaire 
(35, 36). Patients who participated in both the euglycemic and the hypoglyce-
mic clamp had these experiments scheduled in random order at least 2 weeks 
apart. Female subjects were tested at 4- or 8-week intervals to ensure that 
experiments took place during corresponding periods of the menstrual cycle.
Hyperinsulinemic glucose clamps
The experimental procedure has been described in detail before (5, 10). All 
patients came to the MR research facility at 8 AM, after an overnight fast 
and after having abstained from alcohol and caffeine-containing substances 
for 24 hours. Patients were instructed to reduce the basal insulin dose by 
25% the evening before the clamp to avoid hypoglycemic incidents, to check 
their blood glucose level at approximately 2 AM, to omit the insulin dose 
on the morning of the clamp, and (if applicable) to disconnect the insulin 
pump at 7 AM. If hypoglycemia occurred in the 24 hours before the clamp, 
experiments were rescheduled. After arrival at the MR facility, the brachial 
artery of the nondominant arm was cannulated under local anesthesia for 
frequent blood sampling. An intravenous catheter was inserted in the ante-
cubital vein of the contralateral arm for administration of 13C-glucose and 
insulin. Before patients were placed in the scanner, low-dose insulin was 
infused to normalize plasma glucose levels (5–8 mmol/l). MR reference mea-
surements were acquired for 30 minutes without administration of exoge-
nous 13C-labeled glucose, followed by a hyperinsulinemic (60 mU/min/m2) 
Figure 7
VTCA versus HbA1C. Inverse correlation between the HbA1C and the VTCA 
(r = 0.56, P < 0.01). For paired measurements, the average VTCA was 
used. Individual symbols represent individual samples.
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euglycemic (5.0 mmol/l) or hypoglycemic (3.0 mmol/l) glucose clamp. A 30 
ml bolus of 100%-enriched [1-13C]glucose (20% w/w) (Campro Scientific) was 
given 5 minutes after the start of insulin administration to rapidly increase 
plasma glucose 13C enrichment, followed by variable infusions of 40%- or 
50%-enriched [1-13C]glucose (20% w/w) during the euglycemic and hypo-
glycemic experiments, respectively. Blood was sampled every 5 minutes for 
immediate determination of plasma glucose (Beckman Glucose Analyzer II, 
Coulter, or Biosen C-line, EKF Diagnostics) and lactate (Biosen C-line, EKF 
Diagnostics) and for later measurement of plasma 13C isotopic enrichment 
of glucose and lactate by high-resolution proton nuclear MR (1H NMR) at 
500 MHz (37, 38). At baseline, at t = 30 minutes after the start of the clamp 
and at the end of the clamp, additional blood was sampled for measurement 
of plasma insulin and counterregulatory hormones, as described previously 
(10). The clamps were terminated after 100 minutes.
MR protocol
MR experiments were conducted with the same protocol applied to the healthy 
volunteers (5) on a 3T MR system (Magnetom Trio, Siemens) equipped with a 
home-built 1H volume coil, with a circularly polarized 13C surface coil inserted 
into it (39). Transversal T2-weighted images were acquired to locate the voxel 
position for the spectroscopy experiment. Shimming was performed with an 
automatic gradient-echo–based shim sequence. 13C MR spectra were acquired 
with the ISIS-DEPT sequence (40), which combines 1H-ISIS localization with 
1H-13C polarization transfer. A 45° alpha pulse was used to observe 13C-MR 
signals from CH, CH2, and CH3 groups simultaneously. Broadband proton 
decoupling (WALTZ-16; ref. 41) was applied to simplify the MR spectra. MR 
spectra were acquired from a voxel of approximately 125 ml in the occipital 
brain tissue. Each spectrum consisted of 72 scans with a TR of 2 seconds, 
resulting in a total duration of 2.5 minutes. Acquisition of 13C MR spectra 
started 20 minutes before [1-13C]glucose infusion to obtain 8 reference spectra 
and continued throughout the entire clamp. Visual stimulation was avoided 
by dimming the lights in the magnet room during the experiments.
Data analysis
13C MRS data processing and quantification. To remove contamination of nat-
ural abundance 13C MR signals, averaged reference spectra were subtracted 
from the dynamic spectra acquired during 13C-labeled glucose infusion. 
After application of a moving average of 15 minutes, the peaks of interest 
in the spectra were fitted with the advanced MR (AMARES) algorithm (42) 
in the Java-based MR user interface (jMRUI) software package (ref. 43 and 
see Figure 3 for representative spectrum). To quantify the concentrations 
of 13C-labeled metabolites (i.e., Glu4 and Glu3), the natural abundance myo
-inositol (mI) concentration was used, assuming that mI peaks equaled 
1.1% of 6 μmol/g (44). The ratio between the mI concentration and the 
peak integral was derived from the sum of all spectra before baseline cor-
rection. Results from phantom measurements were used to correct for the 
effect of the pulse profiles on the signal intensities.
Metabolic modeling. A standard one-compartment metabolic model (11, 45, 
46) was used to determine rates of metabolic fluxes representing the VTCA, 
the loss of label through exchange with unlabeled glutamine (Vefflux), and 
the exchange of intracellular lactate with plasma lactate (Vdil). The model was 
adapted to include inflow from labeled plasma lactate. A series of differential 
equations describe the fluxes of 13C labels from and to different metabolite 
pools. Plasma glucose and lactate concentrations and 13C isotopic enrich-
ments were used as input for the metabolic model. The time courses of label 
incorporation into glutamate at the C4 (Glu4) and C3 (Glu3) positions were 
fitted with a nonlinear least-squares minimization algorithm in MATLAB 
2008 (MathWorks). This results in values for the flux parameters. This anal-
ysis was performed on all data sets of individual measurements. Note that 
since the current model used the exact lactate concentration input curves, 
rather than approximations, the flux values in the healthy volunteers dif-
fered slightly, but not significantly, from those reported previously (5).
Statistics. All data are expressed as mean ± SD, unless mentioned other-
wise. Differences in means were tested by 2-tailed Student’s t tests, and the 
relationship between HbA1C and VTCA was derived with linear regression 
analysis. Graphpad Prism 4 (Graphpad) was used for statistical analysis, 
and a P value of less than 0.05 was considered statistically significant.
Study approval
All patients gave written informed consent before participating in this 
study, which was approved by the institutional review board of the Rad-
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 Patients with T1DM
Male/female (n) 4/6
BMI (kg/m2) 22.9 ± 3.1
HbA1C (%) 7.6 ± 1.4
Age at first clamp (yr) 31.2 ± 7.8
Duration of diabetes (yr) 15 ± 8
Age of diabetes onset (yr) 17 ± 12
Diabetes onset before 10 years of age (n) 3/10 (30%)
Educational level (n)A 2/3/5
AEducational level was split into the following groups: only secondary 
school/higher vocational education/university degree.
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